MISSION abort after Nexavar fails again in NSCLC
This article was originally published in Scrip
Bayer and Onyx Pharmaceuticals' targeted anticancer Nexavar (sorafenib) has failed in another Phase III study in non-small cell lung cancer, this time in more advanced patients.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.